Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC

Wang, KW; Du, RBY; Roy-Chowdhuri, S; Li, ZT; Hong, LZ; Vokes, N; Elamin, YY; Hume, CB; Skoulidis, F; Gay, CM; Blumenschein, G; Fossella, FV; Tsao, A; Zhang, JJ; Karachaliou, N; O'Brate, A; Gann, CN; Lewis, J; Rinsurongkawong, W; Lee, JJ; Gibbons, DL; Vaporciyan, AA; Heymach, JV; Altan, M; Le, XN

Le, XN (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Unit 432, Houston, TX 77030 USA.

JTO CLINICAL AND RESEARCH REPORTS, 2023; 4 (8):

Abstract

Introduction: MET amplification is a known resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) treat-ment in EGFR-mutant NSCLC. Dual EGFR-MET......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索